TB-500 and tissue repair: separating signal from noise

A careful read of what TB-500 has and has not been shown to do in the published literature.

TL;DR

• TB-500 is a synthetic fragment of thymosin beta-4, a protein the body uses during wound repair.
• Animal studies consistently report faster wound closure and new blood-vessel formation; human trials are small and limited to a few conditions.
• TB-500 is FDA Category 2 in the U.S. and not currently available from 503A compounding pharmacies.

What it is

TB-500 is a 17-amino-acid fragment of thymosin beta-4 (in plain English: a small repair protein that almost every cell in the body makes). Think of thymosin beta-4 as a maintenance crew that shows up after damage — recruiting cells, building new blood vessels, and clearing debris. TB-500 was originally synthesized as a tool to study that crew without using the full-length protein (Crockford et al., Ann N Y Acad Sci, 2010).

How it works

Thymosin beta-4 binds to G-actin (in plain English: a building-block protein that cells use to change shape and move). When a wound forms, cells need to migrate into the gap and reorganize. TB-500 increases the pool of actin that is "ready to build," which speeds the early steps of repair. The molecule also signals new blood-vessel formation, called angiogenesis. Picture a damaged garden: actin is the soil, angiogenesis is the irrigation, and TB-500 is the gardener calling for both at once.

Who asks about it

People come to TB-500 because they have read on a sports-recovery forum that it accelerates healing of tendons, muscles, and joints. They want to know whether the human evidence supports the animal results — and whether the compound is even available in the U.S.

What the research says

In rodent studies, TB-500 and thymosin beta-4 have been associated with faster healing of skin wounds, corneal injuries, and heart muscle after a heart attack (Goldstein et al., Ann N Y Acad Sci, 2012). Phase 2 trials of full-length thymosin beta-4 (developed by RegeneRx) studied dry eye disease, pressure ulcers, and acute myocardial infarction, with mixed but generally favorable safety signals. Trials of TB-500 specifically in athletic recovery have not been published. The signal in animals is strong; the signal in humans is suggestive but thin.

What to know before considering it

The animal-to-human translation gap is the central issue. TB-500 has not been studied in healthy adults for off-label recovery use. As a Category 2 peptide, it is not currently available from 503A compounding pharmacies in the U.S. Material sold online as "research use only" is gray-market and not regulated for human use. Any potential therapeutic use would require a licensed clinician and an FDA-approved supply.

The Halftime POV

TB-500 sits in the "biologically plausible, clinically unproven" bucket. The mechanism is well-described, the animal data is consistent, and the human data is too sparse to support recovery claims. We watch the regulatory path and the next round of human trials. We do not endorse gray-market sourcing.

Related reading:

• TB-500 (thymosin beta-4): what this repair peptide is
• How TB-500 promotes angiogenesis and tissue healing
• TB-500: what Category 2 status means for access
• BPC-157: 30 years of animal research, what it tells us

---

FAQ

Q: What does TB-500 actually do? A: TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein. In animal studies it has been associated with faster wound closure, new blood-vessel formation, and reduced scarring. Most of the data is preclinical.

Q: Are there human trials for TB-500? A: A small number of early-phase studies have examined the parent compound thymosin beta-4 in dry eye disease, pressure ulcers, and acute heart injury. Trials of TB-500 specifically in healthy adults for athletic recovery have not been published.

Q: Is TB-500 available in the United States? A: Not currently through 503A compounding pharmacies. The FDA classified TB-500 (thymosin beta-4) as Category 2, which restricts compounding. A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal Federal Register notice.

---

Disclaimer

As of 2026-05-13, several peptides discussed in this article — including TB-500 (thymosin beta-4) — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.

---

Sources

• Crockford D et al., Thymosin beta-4: structure, function, and biological properties supporting current and future clinical applications — Ann N Y Acad Sci, 2010
• Goldstein AL et al., Thymosin beta-4 in regenerative medicine — Ann N Y Acad Sci, 2012

---

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.